DOP2018000134A - Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer - Google Patents

Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer

Info

Publication number
DOP2018000134A
DOP2018000134A DO2018000134A DO2018000134A DOP2018000134A DO P2018000134 A DOP2018000134 A DO P2018000134A DO 2018000134 A DO2018000134 A DO 2018000134A DO 2018000134 A DO2018000134 A DO 2018000134A DO P2018000134 A DOP2018000134 A DO P2018000134A
Authority
DO
Dominican Republic
Prior art keywords
tiadiazol
compounds
cancer treatment
methylpyridazin
methoxy
Prior art date
Application number
DO2018000134A
Other languages
English (en)
Spanish (es)
Inventor
Raymond Verschoyle Finlay Maurice
David Charles Mark
Wilhelmus Johannes Nissink Maria
James Wood Matthew
Original Assignee
Astrazeneca Ab
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Cancer Research Tech Ltd filed Critical Astrazeneca Ab
Publication of DOP2018000134A publication Critical patent/DOP2018000134A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DO2018000134A 2015-11-30 2018-05-29 Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer DOP2018000134A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562260787P 2015-11-30 2015-11-30

Publications (1)

Publication Number Publication Date
DOP2018000134A true DOP2018000134A (es) 2018-06-30

Family

ID=57421876

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2018000134A DOP2018000134A (es) 2015-11-30 2018-05-29 Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer

Country Status (25)

Country Link
US (1) US9938265B2 (cg-RX-API-DMAC7.html)
EP (1) EP3383871B1 (cg-RX-API-DMAC7.html)
JP (1) JP6873132B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180083412A (cg-RX-API-DMAC7.html)
CN (1) CN108349967B (cg-RX-API-DMAC7.html)
AR (1) AR106876A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016363719B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018010812A2 (cg-RX-API-DMAC7.html)
CA (1) CA3005516C (cg-RX-API-DMAC7.html)
CL (1) CL2018001408A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018006929A2 (cg-RX-API-DMAC7.html)
DK (1) DK3383871T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2018000134A (cg-RX-API-DMAC7.html)
EA (1) EA201891240A1 (cg-RX-API-DMAC7.html)
ES (1) ES2759940T3 (cg-RX-API-DMAC7.html)
IL (1) IL258644A (cg-RX-API-DMAC7.html)
MX (1) MX2018006528A (cg-RX-API-DMAC7.html)
NI (1) NI201800065A (cg-RX-API-DMAC7.html)
PE (1) PE20181450A1 (cg-RX-API-DMAC7.html)
PH (1) PH12018501132A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201803813UA (cg-RX-API-DMAC7.html)
SV (1) SV2018005701A (cg-RX-API-DMAC7.html)
TN (1) TN2018000126A1 (cg-RX-API-DMAC7.html)
TW (1) TW201730188A (cg-RX-API-DMAC7.html)
WO (1) WO2017093300A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
TW201731511A (zh) * 2015-11-30 2017-09-16 阿斯特捷利康公司 １，３，４-噻二唑化合物及其在治療癌症中之用途
TW201733587A (zh) * 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
CN112888686B (zh) * 2018-10-16 2022-04-19 南京明德新药研发有限公司 噻二唑衍生物及其作为gls1抑制剂的应用
WO2025196446A1 (en) * 2024-03-22 2025-09-25 Sitryx Therapeutics Limited Thiadiazoles as glutaminase 1 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE377011T1 (de) * 1999-11-24 2007-11-15 Merck & Co Inc Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmer
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
MY142655A (en) * 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
EP1828144A2 (en) * 2004-11-12 2007-09-05 OSI Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
AU2010241084B2 (en) * 2009-04-20 2014-10-23 F. Hoffmann-La Roche Ag Proline derivatives as cathepsin inhibitors
SG11201402305WA (en) 2011-11-21 2014-06-27 Calithera Biosciences Inc Heterocyclic inhibitors of glutaminase
US10793535B2 (en) * 2012-11-16 2020-10-06 Calithera Biosciences, Inc. Heterocyclic glutaminase inhibitors
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
CN105960405B (zh) * 2014-01-06 2021-02-19 理森制药股份公司 谷氨酰胺酶抑制剂
WO2015138902A1 (en) * 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
TW201731511A (zh) 2015-11-30 2017-09-16 阿斯特捷利康公司 １，３，４-噻二唑化合物及其在治療癌症中之用途
TW201733587A (zh) * 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途

Also Published As

Publication number Publication date
MX2018006528A (es) 2019-05-15
ES2759940T8 (es) 2020-05-20
IL258644A (en) 2018-06-28
CO2018006929A2 (es) 2018-10-10
ES2759940T3 (es) 2020-05-12
NI201800065A (es) 2018-10-18
PH12018501132A1 (en) 2019-01-21
PE20181450A1 (es) 2018-09-12
AU2016363719B2 (en) 2019-11-14
JP2019501134A (ja) 2019-01-17
TW201730188A (zh) 2017-09-01
EP3383871A1 (en) 2018-10-10
SV2018005701A (es) 2018-11-27
SG11201803813UA (en) 2018-06-28
EA201891240A1 (ru) 2018-11-30
JP6873132B2 (ja) 2021-05-19
TN2018000126A1 (en) 2019-10-04
DK3383871T3 (da) 2019-12-16
CL2018001408A1 (es) 2018-10-12
CA3005516A1 (en) 2017-06-08
US9938265B2 (en) 2018-04-10
WO2017093300A1 (en) 2017-06-08
AR106876A1 (es) 2018-02-28
CN108349967A (zh) 2018-07-31
KR20180083412A (ko) 2018-07-20
CA3005516C (en) 2024-04-16
AU2016363719A8 (en) 2018-07-12
US20170152254A1 (en) 2017-06-01
EP3383871B1 (en) 2019-09-11
AU2016363719A1 (en) 2018-07-05
BR112018010812A2 (pt) 2018-11-27
CN108349967B (zh) 2022-02-15

Similar Documents

Publication Publication Date Title
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
MX388748B (es) Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak.
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
DOP2018000134A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
UA118149C2 (uk) Інгібітор jak
MX2023000418A (es) Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia.
CL2017001209A1 (es) Inhibidor de cinasa aurora a
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
AR103680A1 (es) Inhibidores selectivos de bace1
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
SG10201804026WA (en) Inhibitors of influenza viruses replication
PE20170148A1 (es) Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
CR20180328A (es) Compuestos de isoindol
EA201691566A1 (ru) Применение производных пиридазина для предупреждения или лечения атаксического синдрома
CL2017002960A1 (es) Compuesto para la profilaxis o el tratamiento de daño al órgano
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
AR106849A1 (es) Compuestos de bis-piridazina y su uso en el tratamiento del cáncer
MX2018014081A (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
PH12017500487A1 (en) Use of heterocyclic fluoroalkenyl sulfone compounds for repelling molluscs